MX2009006360A - Derivados de dihidrobenzofuranilo y metodos para su uso. - Google Patents

Derivados de dihidrobenzofuranilo y metodos para su uso.

Info

Publication number
MX2009006360A
MX2009006360A MX2009006360A MX2009006360A MX2009006360A MX 2009006360 A MX2009006360 A MX 2009006360A MX 2009006360 A MX2009006360 A MX 2009006360A MX 2009006360 A MX2009006360 A MX 2009006360A MX 2009006360 A MX2009006360 A MX 2009006360A
Authority
MX
Mexico
Prior art keywords
derivatives
dihydrobenzofuranyl
methods
disorders
disorder
Prior art date
Application number
MX2009006360A
Other languages
English (en)
Inventor
Eugene John Trybulski
Eugene Anthony Terefenko
Puwen Zhang
Joseph P Sabatucci
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009006360A publication Critical patent/MX2009006360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se dirige a derivados dihidrobenzofuranilo de la Fórmula I: (ver fórmula (I)) o su sal farmacéuticamente aceptable, que son inhibidores de retorna monoarnina, composiciones que contienen estos derivados, y métodos para su uso para la prevención y tratamiento de afecciones, que incluyen, inter alia, síntomas vasomotrices disfunción sexual, trastornos gastrointestinales y trastorno genitourinario, trastornos de depresión, trastorno del comportamiento endógeno, trastorno cognitivo, neuropatía diabética, dolor, y otras enfermedades o trastornos.
MX2009006360A 2006-12-12 2007-12-12 Derivados de dihidrobenzofuranilo y metodos para su uso. MX2009006360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86964606P 2006-12-12 2006-12-12
PCT/US2007/087103 WO2008073943A1 (en) 2006-12-12 2007-12-12 Dihydrobenzofuranyl derivatives and methods of their use

Publications (1)

Publication Number Publication Date
MX2009006360A true MX2009006360A (es) 2009-06-26

Family

ID=39227094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006360A MX2009006360A (es) 2006-12-12 2007-12-12 Derivados de dihidrobenzofuranilo y metodos para su uso.

Country Status (6)

Country Link
US (1) US20080153873A1 (es)
EP (1) EP2091933A1 (es)
JP (1) JP2010512420A (es)
CA (1) CA2672464A1 (es)
MX (1) MX2009006360A (es)
WO (1) WO2008073943A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088246A1 (ja) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
ES2618812T3 (es) 2011-01-20 2017-06-22 Merck Sharp & Dohme Corp. Antagonistas del receptor mineralocorticoide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20060252818A1 (en) * 2005-05-06 2006-11-09 Neurocrine Biosciences, Inc. Monoamine re-uptake inhibitors and methods relating thereto

Also Published As

Publication number Publication date
US20080153873A1 (en) 2008-06-26
EP2091933A1 (en) 2009-08-26
WO2008073943A1 (en) 2008-06-19
CA2672464A1 (en) 2008-06-19
JP2010512420A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
MX2009006359A (es) Derivados de aril sulfamida y metodos para su uso.
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MX2009008159A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011005242A (es) Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
EA201270012A1 (ru) Сублингвальный апоморфин
EA200801738A1 (ru) Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2009003981A (es) Agentes moduladores del receptor de calcio.
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
NO20085051L (no) Behandling av gastrointestinale forstyrrelser med CGRP-antagonister
IL193252A0 (en) N-hydroxyacrylamide compounds
UA102379C2 (ru) Производные 7-азаиндола как селективные ингибиторы бета-гидроксистероида дегидрогеназы 1 типа
UA105649C2 (uk) Хінолонова сполука і фармацевтична композиція
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
MX2012007005A (es) Tiazoles biciclicos como moduladores alostericos de recptores de glutamato metabotropico subtipo 5.
IL174539A0 (en) Substituted aryl cycloalkanol derivatives and methods of their use
MX2009006360A (es) Derivados de dihidrobenzofuranilo y metodos para su uso.
ATE418553T1 (de) Histamin-h3-rezeptor inhibitoren, ihre herstellung und therapeutische anwendungen
WO2012061019A3 (en) Tricyclic mglur5 receptor modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal